Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC … – Cancer Therapy Advisor
Oncology Nurse AdvisorDual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC …Cancer Therapy AdvisorAtezolizumab (Tecentriq) combined with bevacizumab (Avastin) demonstrated antitumor activity compared with sunitinib as first-line therapy… Continue reading
